Literature DB >> 16837569

Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes.

Emilie Jigorel1, Marc Le Vee, Claire Boursier-Neyret, Yannick Parmentier, Olivier Fardel.   

Abstract

Sinusoidal and canalicular hepatic drug transporters constitute key factors involved in drug elimination from liver. Regulation of their expression via activation of xenosensors, such as aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), pregnane X receptor (PXR), and nuclear factor E2-related factor 2 (Nrf2), remains incompletely characterized. The present study was therefore designed to carefully analyze expression of major drug transporters in primary human hepatocytes exposed to dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) (an AhR activator), rifampicin (RIF) (a PXR activator), phenobarbital (PB) (a CAR activator), and oltipraz (OPZ) (a Nrf2 activator), using mainly reverse transcription-real time polymerase chain reaction assays. With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF. MDR1 and BCRP expression was also increased by TCDD- and RIF-augmented mRNA levels of the influx transporter OATP-C. Bile acid transporters, i.e., bile salt export pump and Na(+)-taurocholate cotransporting polypeptide, and the sinusoidal transporter, OAT2, were down-regulated by all the tested chemicals. Influx transporters such as OCT1, OATP-B, and OATP8 were repressed by PB and TCDD. PB also decreased MRP6 expression, whereas mRNA levels of OCT1 and OATP8 were down-regulated by RIF and OPZ, respectively. Taken together, these data establish a complex pattern of transporter regulation by xenobiotics in human hepatocytes, in addition to interindividual variability in responsiveness. This may deserve further attention with respect to drug-drug interactions and adverse effects of hepatic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837569     DOI: 10.1124/dmd.106.010033

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  81 in total

1.  Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.

Authors:  Alessandro Schipani; Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Marco Simiele; Stefano Bonora; Sonia Rodríguez Novoa; Lorena Cuenca; Vincent Soriano; Nitipatana Chierakul; Natpratou Saguenwong; Charoen Chuchuttaworn; Janelle M Hoskins; Anne M Dvorak; Howard L McLeod; Gerry Davies; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.

Authors:  Antonia H Tolson; Hongbing Wang
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

3.  Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.

Authors:  Kirk D Fowers; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2012-01-25       Impact factor: 4.979

4.  Nrf2 target genes are induced under marginal selenium-deficiency.

Authors:  Mike Müller; Antje Banning; Regina Brigelius-Flohé; Anna Kipp
Journal:  Genes Nutr       Date:  2010-01-29       Impact factor: 5.523

Review 5.  Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.

Authors:  Ahsan N Rizwan; Gerhard Burckhardt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

6.  Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.

Authors:  Amélie Moreau; Marc Le Vée; Elodie Jouan; Claire Denizot; Yannick Parmentier; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

7.  The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.

Authors:  Miao Hu; Sandra S H Lui; Lai-Shan Tam; Edmund K Li; Brian Tomlinson
Journal:  J Lipid Res       Date:  2012-04-24       Impact factor: 5.922

Review 8.  Transporters in the intestine limiting drug and toxin absorption.

Authors:  R P J Oude Elferink; R de Waart
Journal:  J Physiol Biochem       Date:  2007-03       Impact factor: 4.158

9.  Phase I to II cross-induction of xenobiotic metabolizing enzymes: a feedforward control mechanism for potential hormetic responses.

Authors:  Qiang Zhang; Jingbo Pi; Courtney G Woods; Melvin E Andersen
Journal:  Toxicol Appl Pharmacol       Date:  2009-04-14       Impact factor: 4.219

10.  Direct visualization of functional heterogeneity in hepatobiliary metabolism using 6-CFDA as model compound.

Authors:  Chih-Ju Lin; Feng-Chieh Li; Yu-Yang Lee; Te-Yu Tseng; Wei-Liang Chen; Vladimir Hovhannisyan; Ning Kang; Nicholas G Horton; Shu-Jen Chiang; Chris Xu; Hsuan-Shu Lee; Chen-Yuan Dong
Journal:  Biomed Opt Express       Date:  2016-08-19       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.